OBJECTIVE:Shortening of telomere length has been reported in several conditions including Type 2 diabetes and atherosclerosis. The aims of this study were (1) to assess whether telomere shortening occurs at the stage of pre-diabetes, i.e., impaired glucose tolerance (IGT) and (2) whether telomere shortening was greater in Type 2 diabetic subjects with atherosclerotic plaques. METHODS:Subjects with impaired glucose tolerance (IGT) (n=30), non-diabetic control subjects (n=30), Type 2 diabetic patients without (n=30) and with atherosclerotic plaques (n=30) were selected from the Chennai Urban Rural Epidemiology Study (CURES), an ongoing epidemiological population-based study. Southern-blot analysis was used to determine mean terminal restriction fragment (TRF) length, a measure of average telomere size, in leukocyte DNA. Levels of thiobarbituric acid reactive substances (TBARS), protein carbonyl content (PCO) and high sensitive C-reactive protein (hs-CRP) were measured by standard methodologies. Carotid intima-media thickness (IMT) was assessed by high resolution B-mode ultrasonography. RESULTS: The mean (+/-S.E.) TRF lengths were significantly lower in IGT subjects (6.97+/-0.3 kb; p=0.002) and lower still in Type 2 diabetic subjects without plaques (6.21+/-0.2; p=0.0001) and lowest in Type 2 diabetic subjects with atherosclerotic plaques (5.39+/-0.2; p=0.0001) when compared to control subjects (8.7+/-0.5). In IGT subjects, TRF length was positively correlated to HDL cholesterol and negatively correlated to glycated hemoglobin (HbA1c), TBARS, PCO, HOMA-IR and IMT. In multiple linear regression analysis, presence of diabetes, HDL cholesterol and increased TBARS levels appear as significant determinants of telomere shortening. CONCLUSION: Telomere shortening is seen even at the stage of IGT. Among subjects with Type 2 diabetes, those with atherosclerotic plaques had greater shortening of telomere length compared to those without plaques.
RCT Entities:
OBJECTIVE: Shortening of telomere length has been reported in several conditions including Type 2 diabetes and atherosclerosis. The aims of this study were (1) to assess whether telomere shortening occurs at the stage of pre-diabetes, i.e., impaired glucose tolerance (IGT) and (2) whether telomere shortening was greater in Type 2 diabetic subjects with atherosclerotic plaques. METHODS: Subjects with impaired glucose tolerance (IGT) (n=30), non-diabetic control subjects (n=30), Type 2 diabeticpatients without (n=30) and with atherosclerotic plaques (n=30) were selected from the Chennai Urban Rural Epidemiology Study (CURES), an ongoing epidemiological population-based study. Southern-blot analysis was used to determine mean terminal restriction fragment (TRF) length, a measure of average telomere size, in leukocyte DNA. Levels of thiobarbituric acid reactive substances (TBARS), protein carbonyl content (PCO) and high sensitive C-reactive protein (hs-CRP) were measured by standard methodologies. Carotid intima-media thickness (IMT) was assessed by high resolution B-mode ultrasonography. RESULTS: The mean (+/-S.E.) TRF lengths were significantly lower in IGT subjects (6.97+/-0.3 kb; p=0.002) and lower still in Type 2 diabetic subjects without plaques (6.21+/-0.2; p=0.0001) and lowest in Type 2 diabetic subjects with atherosclerotic plaques (5.39+/-0.2; p=0.0001) when compared to control subjects (8.7+/-0.5). In IGT subjects, TRF length was positively correlated to HDL cholesterol and negatively correlated to glycated hemoglobin (HbA1c), TBARS, PCO, HOMA-IR and IMT. In multiple linear regression analysis, presence of diabetes, HDL cholesterol and increased TBARS levels appear as significant determinants of telomere shortening. CONCLUSION: Telomere shortening is seen even at the stage of IGT. Among subjects with Type 2 diabetes, those with atherosclerotic plaques had greater shortening of telomere length compared to those without plaques.
Authors: Jennifer Daubenmier; Jue Lin; Elizabeth Blackburn; Frederick M Hecht; Jean Kristeller; Nicole Maninger; Margaret Kuwata; Peter Bacchetti; Peter J Havel; Elissa Epel Journal: Psychoneuroendocrinology Date: 2011-12-14 Impact factor: 4.905
Authors: S J Ives; R H I Andtbacka; S-Y Park; A J Donato; J R Gifford; R D Noyes; L A Lesniewski; R S Richardson Journal: Acta Physiol (Oxf) Date: 2012-08-06 Impact factor: 6.311
Authors: Marij Gielen; Geja J Hageman; Evangelia E Antoniou; Katarina Nordfjall; Massimo Mangino; Muthuswamy Balasubramanyam; Tim de Meyer; Audrey E Hendricks; Erik J Giltay; Steven C Hunt; Jennifer A Nettleton; Klelia D Salpea; Vanessa A Diaz; Ramin Farzaneh-Far; Gil Atzmon; Sarah E Harris; Lifang Hou; David Gilley; Iiris Hovatta; Jeremy D Kark; Hisham Nassar; David J Kurz; Karen A Mather; Peter Willeit; Yun-Ling Zheng; Sofia Pavanello; Ellen W Demerath; Line Rode; Daniel Bunout; Andrew Steptoe; Lisa Boardman; Amelia Marti; Belinda Needham; Wei Zheng; Rosalind Ramsey-Goldman; Andrew J Pellatt; Jaakko Kaprio; Jonathan N Hofmann; Christian Gieger; Giuseppe Paolisso; Jacob B H Hjelmborg; Lisa Mirabello; Teresa Seeman; Jason Wong; Pim van der Harst; Linda Broer; Florian Kronenberg; Barbara Kollerits; Timo Strandberg; Dan T A Eisenberg; Catherine Duggan; Josine E Verhoeven; Roxanne Schaakxs; Raffaela Zannolli; Rosana M R Dos Reis; Fadi J Charchar; Maciej Tomaszewski; Ute Mons; Ilja Demuth; Andrea Elena Iglesias Molli; Guo Cheng; Dmytro Krasnienkov; Bianca D'Antono; Marek Kasielski; Barry J McDonnell; Richard Paul Ebstein; Kristina Sundquist; Guillaume Pare; Michael Chong; Maurice P Zeegers Journal: Am J Clin Nutr Date: 2018-09-01 Impact factor: 7.045
Authors: Mykola Khalangot; Dmytro Krasnienkov; Alexander Vaiserman; Ivan Avilov; Volodymir Kovtun; Nadia Okhrimenko; Alexander Koliada; Victor Kravchenko Journal: Exp Biol Med (Maywood) Date: 2017-01-01